scholarly journals Treatment cost of metastatic colon cancer in Turkey

2013 ◽  
Vol 14 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Guvenc Kockaya ◽  
Mine Polat ◽  
Albert Wertheimer ◽  
Ahmet Ozet ◽  
Simten Malhan ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Life Expectancy ◽  
Cancer Treatment ◽  
Cost Of Care ◽  
University Hospital ◽  
Hospital Treatment ◽  
Metastatic Colon Cancer ◽  
Treatment Protocols ◽  
Total Cost ◽  
The Cost

OBJECTIVES: Colon cancer is the third most common in the top cancer incidence list in Europe. In Europe 212,000 patients die every year due to colon cancer. In Turkey 120,000-130,000 new cancer patients are diagnosed every year, 7.1% of whom are diagnosed to have developed colon cancer. Metastases will occur in up to 50% of the patients who are newly diagnosed. Survival appears to be further prolonged to more than 20 months with new pharmaceuticals; however, these new pharmaceuticals increase the total cost of care. The aim of this study is to estimate the cost implications of new colon cancer treatment options for Turkey.METHODS: Gazi University Hospital treatment protocols for colon cancer treatment were used. Cost of FUFA (5 FU/LV), FOLFIRI, FOLFOX, bevacizumab/FUFA, bevacizumab/FOLFIRI, bevacizumab/FOLFOX, irinotecan and irinotecan/cetixumab protocols were calculated. The cost of combination of protocols were calculated depending on a Markov analysis. The exchange rate was US$ 1 for TL 1.5.RESULTS: Depending on the life expectancy the lowest total cost was established by FUVA (US$ 5,359). It was followed by FOLFIRI then FOLFOX and FOLFOX, US$ 14,144 and US$ 16,553, respectively. The lowest cost for each week of life expectancy was established by FUVA with US$ 98.CONCLUSIONS: Only FUFA, FOLFIRI followed by FOLFIX, FOLFIRI/bevacizumab then FOLFOX then cetuximab, FOLFOX/bevacizumab then irinotecan then cetuximab/irinotecan and FOLFIRI/bevacizumab then FOLFOX then cetuximab/irinotecan were under the cost effectiveness curve. In addition no treatments ICER was under the WHO`s threshold for Turkey, except FOLFIRI then FOLFOX compared with FUVA.

scholarly journals Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients

2016 ◽  
Vol 22 (6) ◽  
pp. 628-639 ◽  
Author(s):  
Andinet Woldemichael ◽  
Eberechukwu Onukwugha ◽  
Brian Seal ◽  
Nader Hanna ◽  
C. Daniel Mullins
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Metastatic Colon Cancer ◽  
The Cost

Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System

2020 ◽  
Author(s):  
Julia Gonzalez ◽  
Diana Carolina Andrade ◽  
JianLi Niu
Keyword(s):  
Healthcare System ◽  
Treatment Success ◽  
Standard Of Care ◽  
Cost Of Care ◽  
Secondary Outcome ◽  
Total Cost ◽  
Skin Structure ◽  
Cost Consequence ◽  
The Difference ◽  
The Cost

Abstract Background Acute bacterial skin and skin structure infections (ABSSSIs) are common infectious diseases that cause a significant economic burden on the healthcare system. This study aimed to compare the cost-effectiveness of dalbavancin vs standard of care (SoC) in the treatment of ABSSSI in a community-based healthcare system. Methods This was a retrospective study of adult patients with ABSSSI treated with dalbavancin or SoC during a 27-month period. Patients were matched based on age and body mass index. The primary outcome was average net cost of care to the healthcare system per patient, calculated as the difference between reimbursement payments and the total cost to provide care to the patient. The secondary outcome was proportion of cases successfully treated, defined as no ABSSSI-related readmission within 30 days after the initiation of treatment. Results Of the 418 matched patients, 209 received SoC and 209 received dalbavancin. The average total cost of care per patient was greater with dalbavancin vs SoC ($4770 vs $2709, P < .0001). The average reimbursement per patient was $3084 with dalbavancin vs $2633 SoC (P = .527). The net cost, calculated as revenue minus total cost, was $1685 with dalbavancin vs $75 with SoC (P = .013). The overall treatment success rate was 74% with dalbavancin vs 85% with SoC (P = .004). Conclusions Dalbavancin was more costly than SoC for the treatment of ABSSSI, with a higher 30-day readmission rate. Dalbavancin does not offer an economic or efficacy advantage.

Abstract WP382: The Cost of Ischemic Stroke: The Superiority of Marginal over Total Cost Estimation and Its Impact on National Cost Estimates

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Annie N Simpson ◽  
Charles Ellis ◽  
Abby S Kazley ◽  
Heather S Bonilha ◽  
James S Zoller
Keyword(s):  
South Carolina ◽  
Ischemic Stroke ◽  
Cost Of Illness ◽  
Cost Of Care ◽  
Control Group ◽  
Medicare Beneficiaries ◽  
Comorbid Conditions ◽  
Total Cost ◽  
Economic Decision Making ◽  
The Cost

Introduction Cost of illness for ischemic stroke has historically been reported as mean cost per case over a time period. Such cost include expenditures made for comorbid conditions, and may result in an over-estimation of the economic burden of stroke on the nation. Without accurate estimates, policymakers cannot plan appropriately for the ageing US population. Hypothesis The 1-year marginal cost of stroke is less than the 1-year total cost of stroke for South Carolina (SC) Medicare beneficiaries. Methods A cost of illness analysis was performed from the Medicare perspective. SC Medicare billing files for 2004 and 2005 were used to estimate the mean 12 month cost of stroke for 2,976 Medicare beneficiaries hospitalized for ischemic Stroke in 2004. Using nearest neighbor propensity score matching, a control group of 5,952 non-stroke beneficiaries were matched on age, race, gender and comorbid conditions. Results The total cost estimated for stroke patients for 1 year was $81.3 million. The cost for the matched comparison group without stroke, but with similar age, gender, race and comorbid conditions was significantly less at $54.4 million (p<0.0001). Thus, the 2004 marginal costs to Medicare due to ischemic stroke in SC are estimated to be $26.9 million. If this difference is inflated to 2012 dollars and projected to estimate the 2012 one year burden of ischemic stroke nationally, total annual stroke costs would be overestimated by $4.89 billion. Conclusions Accurate estimates of cost of care for conditions, such as stroke, that are common in older patients with a high rate of comorbid conditions require the use of a marginal costing approach. Overestimation of cost of care for stroke may lead to erroneous funding allocation and prediction of larger savings than realizable from stroke treatment and prevention programs. Given the trend of policies based on cost savings, overestimation poses a danger of limiting services that patients may receive. Thus, it is important to use marginal costing for stroke program estimates, especially with the increasing public focus on evidence-based economic decision making to be expected with health reform.

scholarly journals Impact of the Cost of Cancer Treatment: An Internet-Based Survey

2010 ◽  
Vol 6 (2) ◽  
pp. 69-73 ◽  
Author(s):  
Maurie Markman ◽  
Ryan Luce
Keyword(s):  
Cancer Treatment ◽  
Cost Of Care ◽  
Patients With Cancer ◽  
Recommended Treatment ◽  
Cancer Experience ◽  
The Cost ◽  
To Receive

Survey suggests many patients with cancer experience distress associated with cost of care. A serious issue for those with modest annual incomes, these costs affect whether patients decide to receive recommended treatment.

Pharmacy cost in cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18358-e18358
Author(s):  
Surbhi Shah ◽  
Nathan Rubin
Keyword(s):  
Health Care ◽  
Drug Cost ◽  
Economic Burden ◽  
Cancer Care ◽  
Cost Of Care ◽  
Pharmacy Cost ◽  
Health Care Spending ◽  
Total Cost ◽  
The Cost ◽  
Active Cancer

e18358 Background: Health care spending in US is highest in the developed world and contributes to up to 1/5 of the GDP. The price escalation is steep and contribution from cancer care is soaring. The cost of medications is deemed to be the leading cause of increased health care spending. In this era of precision medicine, with more effective and better tolerated drugs, patients are using them for longer periods of time, adding to the ever mounting health care spending. Methods: We used a large claims based data set US database MarketScan to explore the economic burden of drug cost in cancer care. Between January 1, 2013 and September 30, 2015 we identified 195,290 enrollees with active cancer. We analyzed the economic burden of medications for overall cancer care by exploring the total cost of care and the pharmacy expenditure by various classes of drugs for these patients. The perspective was that of the health care system as the costs included payments by the insurer and the patient. Results: There were 195,290 active cancer patients in this analysis. Mean age was 61 years, 55% were females. Breast cancer was the most common diagnosis. Mean total cost of care and total drug cost per patient over the study period was $141,415 and $13,579, respectively. The total pharmacy expenditure across all study patients was ~2.5B. Antineoplastic drugs make up the largest portion of the total pharmacy expenditure at 39%. Cost contribution based on drug categories were anti-infective (6%), cardiovascular (6%), central nervous system (including opiates, anti-nausea medications and antidepressants) (7%), blood formulations (including anticoagulants) (8%), hormones (8%) and gastrointestinal drugs (4%) respectively. Conclusions: Based on the real world information from a large insurance claims database, this study quantifies the contribution of various drug classes to the cost of cancer care. Antineoplastic contribute to > 1/3rd of the total pharmacy spending. With increasing trend for immunotherapy and combination therapy drug costs are bound to go up even more steeply. Unless drug prices are regulated, we are looking towards an unsustainable level of growth in the health care spending in cancer care.

Prophylactic oophorectomy in premenopausal women with non-metastatic colon cancer: A decision analysis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 6130-6130
Author(s):  
S. M. Mourton ◽  
J. P. Hollenberg ◽  
N. R. Abu-Rustum ◽  
D. S. Chi ◽  
W. D. Wong ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Life Expectancy ◽  
Premenopausal Women ◽  
Surgical Excision ◽  
Premature Menopause ◽  
Decision Analytic Model ◽  
Published Data ◽  
Metastatic Colon Cancer ◽  
Prophylactic Oophorectomy ◽  
Trade Off

6130 Background: There is data to suggest that prophylactic oophorectomy (PO) in premenopausal women with colon cancer may improve survival. However, the potential for improved survival must be balanced against the trade-off of premature menopause and its affect on quality of life (QOL). The objective of this study was to determine the value of PO in premenopausal women undergoing surgical excision of colon cancer. Methods: We constructed a decision-analytic model comparing PO versus no PO for premenopausal women undergoing resection of stage I-III colon cancer. The model included detection of ovarian micrometastases (OMM), adjuvant chemotherapy, development of metachronous ovarian metastases, subsequent risk of ovarian cancer and QOL. Probabilities and utilities were estimated from published data. Life expectancy (LE) and quality adjusted LE (QALE) were calculated using the Declining Exponential Approximation of Life Expectancy. Results: With a baseline OMM incidence of 8%, a 5 yr survival of OMM removed (19%) vs OMM left in situ (11%), there was a gain in LE of 2.8 months with PO. With QOL adjustments for menopause (utility 0.77) and colon cancer (utility 0.37–0.85 ), QALE was 1.7 months less with PO. One-way sensitivity analysis (SA) demonstrated that the utility of menopause had the greatest effect on QALE differences, with a threshold value of 0.86 at which QALE was greater with PO. With increasing OMM incidence and 5-year survival with removed OMM, QALE became greater in the PO cohort. All 1, 2, and 3 way SAs demonstrated that the model was robust through the probable range of variables. Conclusions: Our model demonstrated the significant effect of menopause QOL on overall QALE. Although PO may lead to a small gain in LE, the trade-off of premature menopause must be considered when counseling patients. No significant financial relationships to disclose.

Costs and Benefits of Measures to Prevent Needlestick Injuries in a University Hospital

1999 ◽  
Vol 20 (9) ◽  
pp. 614-617 ◽  
Author(s):  
Françoise Roudot-Thoraval ◽  
Olivier Montagne ◽  
Annette Schaeffer ◽  
Marie-Laure Dubreuil-Lemaire ◽  
Danièle Hachard ◽  
...  
Keyword(s):  
Preventive Measures ◽  
Tertiary Care ◽  
University Hospital ◽  
Actual Number ◽  
Costs And Benefits ◽  
Needlestick Injuries ◽  
Total Cost ◽  
Number Of Patients ◽  
The Cost

AbstractObjective:To document the costs and the benefits (both in terms of costs averted and of injuries averted) of education sessions and replacement of phlebotomy devices to ensure that needle recapping did not take place.Design:The percentage of recapped needles and the rate of needlestick injuries were evaluated in 1990 and 1997, from a survey of transparent rigid containers in the wards and at the bedside and from a prospective register of all injuries in the workplace. Costs were computed from the viewpoint of the hospital. Positive costs were those of education and purchase of safer phlebotomy devices; negative costs were the prophylactic treatments and follow-up averted by the reduction in injuries.Setting:A 1,050-bed tertiary-care university hospital in the Paris region.Results:Between the two periods, the proportion of needles seen in the containers that had been recapped was reduced from 10% to 2%. In 1990, 127 needlestick (12.7/100,000 needles) and 52 recapping injuries were reported versus 62 (6.4/100,000 needles) and 22 in 1996 and 1997. When the rates were related to the actual number of patients, the reduction was 76 injuries per year. The total cost of information and preventive measures was $325,927 per year. The cost-effectiveness was $4,000 per injury prevented.Conclusion:Although preventive measures taken to ensure reduction of needlestick injuries appear to have been effective (75% reduction in recapping and 50% reduction in injuries), the cost of the safety program was high.

scholarly journals Financial cost of elective day of surgery cancellations

2018 ◽  
Vol 7 (5) ◽  
pp. 30
Author(s):  
Elina Turunen ◽  
Merja Miettinen ◽  
Leena Setälä ◽  
Katri Vehviläinen-Julkunen
Keyword(s):  
Healthcare Services ◽  
University Hospital ◽  
Financial Loss ◽  
Financial Cost ◽  
Total Cost ◽  
Operative Care ◽  
Time Period ◽  
Cancellation Rate ◽  
The Cost

Operative care is one of the major areas of healthcare services as over 310 million surgeries are conducted yearly. Surgery cancellations is a widely used indicator when evaluating the quality of preoperative care. Cancellations cause financial lost for organizations, however there is only limited research about the costs. The aim of this study was to evaluate the cost of elective day of surgery (DOS) cancellations in 13 operative specialties at a university hospital in Finland between September 1, 2015 and May 31, 2016 after a structured preoperative protocol was implemented to practice and a cancellation rate of 4.7% was recognized. Procedure prices conducted the data for the research and were collected from the hospital’s invoicing system. Financial loss and savings of cancellations were calculated from the total cost of procedures. As a result the total cost of DOS cancellations during the nine-month time period was 953,374.27 euros and mean loss of a single cancelled operation was 2,459.91 euros. The total of material savings for the hospital were 106,917.33 euros. As a conclusion, DOS cancellations cause unnecessary wastage, and financial aspects should be followed and evaluated systematically by setting goals and providing continuing developments.

scholarly journals Cost of care for persons with dementia: using a discrete-time Markov chain approach with administrative and clinical data from the dementia service Centres in Austria

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Alexander Braun ◽  
Paulina Kurzmann ◽  
Margit Höfler ◽  
Gottfried Haber ◽  
Stefanie Auer
Keyword(s):  
Markov Chain ◽  
Clinical Data ◽  
Discrete Time ◽  
Dementia Care ◽  
Cost Of Care ◽  
Severe Dementia ◽  
Discrete Time Markov Chain ◽  
Total Cost ◽  
Cost Increase ◽  
The Cost

Abstract Background There is growing evidence that the cost for dementia care will increase rapidly in the coming years. Therefore, the objective of this paper was to determine the economic impact of treating clients with dementia in outpatient Dementia Service Centres (DSCs) and simulate the cost progression with real clinical and cost data. Methods To estimate the cost for dementia care, real administrative and clinical data from 1341 clients of the DSCs were used to approximate the total cost of non-pharmaceutical treatment and simulate the cost progression with a discrete-time Markov chain (DTMC) model. The economic simulation model takes severity and progression of dementia into account to display the cost development over a period of up to ten years. Results Based on the administrative data, the total cost for treating these 1341 clients of the DSCs came to 67,294,910 EUR in the first year. From these costs, 74% occurred as indirect costs. Within a five-year period, these costs will increase by 7.1-fold (16.2-fold over 10 years). Further, the DTMC shows that the greatest share of the cost increase derives from the sharp increase of people with severe dementia and that the cost of severe dementia prevails the cost in later periods. Conclusion The DTMC model has shown that the cost increase of dementia care is mostly driven by the indirect cost and the increase of severity of dementia within any given year. The DTMC reveals also that the cost for mild dementia will decrease steadily over the time period of the simulation, whereas the cost for severe dementia increases sharply after running the simulation for 3 years.

Hoarseness After Metastatic Colon Cancer Treatment

2014 ◽  
Vol 140 (9) ◽  
pp. 881 ◽  
Author(s):  
Andria M. Caruso ◽  
Tanya K. Meyer ◽  
Clint T. Allen
Keyword(s):  
Colon Cancer ◽  
Cancer Treatment ◽  
Metastatic Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document